MS: is it one disease?

Neuropathological studies of early multiple sclerosis (MS) tissue have shaped prevailing views of the pathogenesis of the disease. The hallmark of the acute MS lesion, inflammatory demyelination, has been largely accepted as evidence of a macrophage-mediated attack on normal myelin, driven by perivascular and parenchymal autoreactive CD4+ Th1 cells primed in the periphery by an unknown self or foreign antigen(s). Predicated largely upon comparisons with experimental allergic encephalomyelitis, this paradigm has, in recent years, been recognized as a simplification of the events that constitute and perhaps presage lesion formation in the human disease; and the importance of the innate immune cells of the central nervous system, humoral factors, cytotoxic CD8+ T-cells and regulatory T-cells has been emphasized. An influential series of publications by one group, based on histopathological examination of actively demyelinating lesions in selected autopsy and biopsy MS tissue, defined four early lesion subtypes. In a given individual, these subtypes were reported to be mutually exclusive, suggesting that disparate pathogenetic pathways separate patients with clinically indistinguishable syndromes. This schema, which has considerable therapeutic implications, has not been independently verified and has recently been questioned by the finding of a uniform pre-phagocytic pathology and overlap of lesion subtypes in individual patients with typical relapsing and remitting disease. The latter findings would suggest that the heterogeneous features observed in active MS lesions sampled at different time-points are a reflection of the evolution of a single pathophysiological process, perhaps modified in part by genetic factors in individual cases.

[1]  David H. Miller,et al.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.

[2]  C. Lucchinetti,et al.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. , 2001, Trends in molecular medicine.

[3]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[4]  Jacqueline Palace,et al.  The effect of anti-α4 integrin antibody on brain lesion activity in MS , 1999, Neurology.

[5]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[6]  J. Prineas,et al.  Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown , 1981, Annals of neurology.

[7]  R. Ravid,et al.  Expression of CCR7 in multiple sclerosis: Implications for CNS immunity , 2004, Annals of neurology.

[8]  C. Polman,et al.  In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology , 2005, Journal of Neuroimmunology.

[9]  J. Zajicek,et al.  Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. , 1992, Brain : a journal of neurology.

[10]  David H. Miller,et al.  Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis , 2004, Journal of Neurology.

[11]  R. Hohlfeld,et al.  Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. , 2002, Brain : a journal of neurology.

[12]  B. Weinshenker,et al.  Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange , 2005, The Lancet.

[13]  Sergio E. Baranzini,et al.  Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets , 2008, Nature.

[14]  M. Barnett,et al.  Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion , 2004, Annals of neurology.

[15]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[16]  A. Bar-Or,et al.  Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions , 2003, Journal of Neuroimmunology.

[17]  L. Bö,et al.  Homogeneity of active demyelinating lesions in established multiple sclerosis , 2008, Annals of neurology.

[18]  H. Lassmann,et al.  CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation , 2002, Nature Medicine.

[19]  M. Barnett,et al.  The pathology of multiple sclerosis: a paradigm shift , 2006, Current opinion in neurology.

[20]  H. Link,et al.  Review: cytokines and the pathogenesis of multiple sclerosis , 1996, Journal of neuroscience research.

[21]  M. Barnett,et al.  The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion , 2006, Multiple sclerosis.

[22]  J. Merrill Proinflammatory and Antiinflammatory Cytokines in Multiple Sclerosis and Central Nervous System Acquired Immunodeficiency Syndrome , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[23]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[24]  L. Boon,et al.  Transfer of Central Nervous System Autoantigens and Presentation in Secondary Lymphoid Organs1 , 2002, The Journal of Immunology.

[25]  C. Raine,et al.  The adhesion molecule and cytokine profile of multiple sclerosis lesions , 1995, Annals of neurology.

[26]  Hans Lassmann,et al.  Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction , 2000, The Journal of experimental medicine.

[27]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[28]  J. Benjamins,et al.  Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[29]  Helmut Butzkueven,et al.  LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival , 2002, Nature Medicine.

[30]  H. Lassmann,et al.  Autoimmunity to Myelin Oligodendrocyte Glycoprotein in Rats Mimics the Spectrum of Multiple Sclerosis Pathology , 1998, Brain pathology.

[31]  Moses Rodriguez,et al.  Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.

[32]  V. Kostulas,et al.  Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. , 1987, Archives of neurology.

[33]  C. Raine,et al.  Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions , 1976, Neurology.

[34]  G. Reichmann,et al.  Brain Dendritic Cells and Macrophages/Microglia in Central Nervous System Inflammation1 , 2001, The Journal of Immunology.

[35]  H. Lipton,et al.  A specific viral cause of multiple sclerosis: One virus, one disease , 2007, Annals of neurology.

[36]  A. Coles,et al.  Campath-1H Treatment of Multiple Sclerosis , 2007, Neurodegenerative Diseases.

[37]  D. Hoyer,et al.  Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. , 2008, Pharmacology & therapeutics.

[38]  H. Lassmann,et al.  Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination , 1998, Annals of neurology.

[39]  S. Ludwin,et al.  Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. , 2005, Brain : a journal of neurology.

[40]  T. Olsson,et al.  Immunoblot detection of oligoclonal anti‐myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis , 1987, Neurology.

[41]  C. Granger,et al.  Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1 , 1999, Journal of Neuroimmunology.

[42]  Hans Lassmann,et al.  Hypoxia-like tissue injury as a component of multiple sclerosis lesions , 2002, Journal of the Neurological Sciences.

[43]  M. Esiri,et al.  The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. , 1997, Brain : a journal of neurology.